Western Blot: PGAM1 Antibody [NBP1-49532] - Analysis of PGAM1 in Jurkat whole cell extracts
Immunocytochemistry/ Immunofluorescence: PGAM1 Antibody [NBP1-49532] - Analysis of PGAM1 in HeLa cells using NBP1-49532. Nuclei (Blue) are counterstained using Hoechst 33258.
Immunohistochemistry: PGAM1 Antibody [NBP1-49532] - Analysis of PGAM1 in mouse tongue.
Simple Western: PGAM1 Antibody [NBP1-49532] - Simple Western lane view shows a specific band for PGAM1 in 0.05 mg/ml of Jurkat lysate. This experiment was performed under reducing conditions using the 12-230 kDa ...read more
This PGAM1 antibody may be used in Western blot, Immunohistochemistry paraffin embedded sections and Immunocytochemistry/Immunofluorescence. In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. Separated by Size-Wes, Sally Sue/Peggy Sue. Knockdown validation (PMID: 28122957).
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
PBS and 30% Glycerol
0.05% Sodium Azide
Immunogen affinity purified
Alternate Names for PGAM1 Antibody
BPG-dependent PGAM 1
PGAM-Bphosphoglycerate mutase 1
phosphoglycerate mutase 1 (brain)
phosphoglycerate mutase A, nonmuscle form
Phosphoglycerate mutase isozyme B
PGAM1 (phosphoglycerate mutase 1) is an enzyme that regulates a unique step in glycolysis, and most of the glycolytic intermediates that are used as precursors for anabolic biosynthesis are upstream of this step. PGAM1 catalyzes the interconversion of 3- phosphoglycerate (3-PGA) to 2- phosphoglycerate (2-PGA), and becomes activated or "primed" by an intrinsic phosphatase activity that converts 2,3-bisphosphoglycerate (2, 3-BPGA) to 2-PGA, phosphorylating the active site histidine in the process. The phosphohistidine is essential to carryout the mutase reaction, converting 3-PGA to 2-PGA in glycolysis. Interestingly, PGAM1 is the rate-limiting enzyme of glycolysis in tumor cells, heart tissue, and leukocytes, and its inhibition by epoxide inhibitors is lethal to cancer cells. In many cancers, including hepatocellular carcinoma and colorectal cancer, PGAM1 activity is increased compared to that in the normal tissues, wherein its expression is upregulated through loss of TP53 as TP53 negatively regulates PGAM1 gene expression.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
FAQs for PGAM1 Antibody (NBP1-49532). (Showing 1 - 1 of 1 FAQs).
This antibody is reactive with human as noted in the datasheet. Can we use this antibody for dog tissues?
Our antibody NBP1-49532 has not yet been tested with dog PGAM1. However, I have run a UniProt Blast sequence comparison of the immunogen sequence (residues 200-254 of the human protein, UniProt P18669) with canine, and the result was 98% homology with canine PGAM1 (UniProt E2RT65). This strongly suggests that this antibody is suitable for use with dog tissues (although we cannot guarantee success). Note that if you decide to go ahead and test this antibody with a new species, you would be eligible for our Innovator's Reward. The details of this program are shown here: Innovator's Reward program.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.